# R1 Clinical-Safety Review — succinate_dehydrogenase_deficient_gist

VERDICT: APPROVE (confidence 88)

Adversarial-verify file (.verdict.md): NOT PRESENT — no prior flagged issues to carry.
Goldens changed: no (intended: n) — narrative content only, no engine/rule/data change.

## 1. SAFETY — pass
No unsafe, misleading, or harmful absolute statement. Where the biology is
absolute the wording is correctly hedged ("essentially not sensitive to
imatinib as a class, though occasional responses have been reported"). The
lymph-node point is safety-POSITIVE: it explicitly warns not to assume nodes
benign by analogy to KIT-mutated GIST, reducing a false-negative risk. The
"managed expectantly" option (metastatic, indolent) is properly bounded with
"some patients / may be" and does not read as a directive to withhold therapy.

## 2. GROUNDING — pass, with one relabel note (Important, not blocking)
The draft is unusually disciplined about attribution: it labels extrapolations
explicitly (line 23 "general oncology standard, not from DeVita's section...";
line 31 "synthesis from DeVita's chapter themes, not a verbatim statement") and
enumerates what DeVita does NOT specify (lines 34-35). Core claims — surgery
primary for localized disease, SDHB IHC to identify the subtype, germline SDHX
counseling, reduced TKI sensitivity, adjuvant TKI not recommended, the
lymph-node exception — are consistent with DeVita/NCCN standard of care. No
fabricated or outdated regimen.
- Line 20 ("sunitinib and regorafenib have shown activity specifically in
  SDH-deficient GIST"): clinically uncontroversial and supported by the wild-type
  GIST literature. The draft does not explicitly attribute it to DeVita, but the
  single trailing "Sources: DeVita..." line could be read as sourcing it there.
  Per R1 rule this is approvable because the claim is uncontroversial; it should
  be understood as general standard-of-care, not a DeVita-specific citation.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, or numbered schedule. "Annual" MRI, "within weeks/months"
are surveillance/kinetic intervals, not drug doses. Clean.

## 4. SCOPE — pass
Consistently framed as decision-support: "individualized," "case-by-case,"
"reasonable extension," "may be managed," "should be considered." No directive
overreach.

## Advisory
- Consider tightening line 20 wording (e.g., "reported to have activity") so the
  general-standard basis is unambiguous versus the DeVita citation line.
- The "What DeVita does not specify" section (34-35) is a strength; keep it.
